Amicus Therapeutics, Inc.
FOLD
Rang in Aktien
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Aktienkurs
$14.49
Zuletzt synchronisiert: 2026-04-27
Marktkapitalisierung
$4.55B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
80.22%
Land
US
Handel Amicus Therapeutics, Inc. (FOLD)
Kategorie
Healthcare
EPS für Amicus Therapeutics, Inc. (FOLD)
EPS zum December 2025 TTM: $-0.09
Laut den aktuellen Finanzberichten und dem Aktienkurs von Amicus Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-0.09. Am Ende des Jahres 2023 betrug das EPS $-0.51 ein Rückgang im Vergleich zu dem EPS von 2022, das $-0.82 betrug.
EPS-Verlauf von Amicus Therapeutics, Inc. von 2003 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-0.09 | -50.83% |
| 2024 | $-0.18 | -64.71% |
| 2023 | $-0.51 | -37.80% |
| 2022 | $-0.82 | -10.87% |
| 2021 | $-0.92 | -14.02% |
| 2020 | $-1.07 | -27.70% |
| 2019 | $-1.48 | -21.28% |
| 2018 | $-1.88 | 1.62% |
| 2017 | $-1.85 | 24.16% |
| 2016 | $-1.49 | 24.17% |
| 2015 | $-1.20 | 29.03% |
| 2014 | $-0.93 | -19.83% |
| 2013 | $-1.16 | 8.41% |
| 2012 | $-1.07 | -16.41% |
| 2011 | $-1.28 | -35.35% |
| 2010 | $-1.98 | 582.76% |
| 2009 | $-0.29 | -83.43% |
| 2008 | $-1.75 | -43.73% |
| 2007 | $-3.11 | -95.06% |
| 2006 | $-62.97 | 29.33% |
| 2005 | $-48.69 | 70.01% |
| 2004 | $-28.64 | 30.12% |
| 2003 | $-22.01 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -19,670.62% |
US
|
|
| $-7.98 | 8,916.95% |
US
|
|
| $-5.29 | 5,877.40% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -31,444.63% |
NL
|
